Skip to main content
. 2020 Nov 7;11(3):708–726. doi: 10.1016/j.apsb.2020.11.002

Figure 9.

Figure 9

SIRT6 activator MDL-811 inhibits inflammatory response in monocytes of patients with ischemic stroke. (A) MDL-811 significantly reduced the mRNA expression of proinflammatory genes (TNF-α, IL-1β and NOS2) but had no effect on SIRT6 mRNA expression in monocytes isolated from stroke patients. Cells were incubated with 1 μmol/L of MDL-811 for 2 h and then stimulated with 50 ng/mL LPS for another 2 h (n = 7). Results were normalized to 18S rRNA. n.s.: no significant, ∗P < 0.05. (B) Western blot analysis on the protein expression of FOXC1, H3K9Ac, H3K56Ac and H3K27me3 in monocytes from stroke patients incubated with 50 ng/mL LPS and 1 μmol/L of MDL-811 (n = 5). H3 is the internal control and β-actin is the loading control. Data are representative of three independent experiments. The experiments were repeated three times on different days. (C) SIRT6 mRNA expression in blood is decreased in ischemic stroke patients as compared to healthy controls (n = 7). Results were normalized to 18S rRNA. The experiments were repeated three times on different days; ∗P < 0.05. (D) There is a linear correlation between SIRT6 transcript levels in blood and anti-inflammatory effect of MDL-811 in monocytes of ischemic stroke patients and healthy controls (n = 14).